January 2019 - INP104 met the predefined statistical criteria for comparative bioavailability with IV DHE and Migranal. The shorter time to reach Cmax and at 4 times the plasma concentration of DHE in comparison to Migranal combined with a favorable tolerability profile support further investigation of INP104 as an effective,...

Crossover Financing to Advance Clinical Development of Central Nervous System Assets in Migraine, Parkinson’s Disease and Acute Agitation SEATTLE, December 6th, 2018 — Impel NeuroPharma (“Impel” or the “Company”), a Seattle-based, privately-held biotechnology company focused on developing therapies for the treatment of central nervous system (“CNS”) disorders with unmet medical needs,...

Our Impel team will be attending Piper Jaffray's 19th Annual  Health Care Conference in New York on November 27 - 29. Management teams from nearly 300 leading public and private companies in biotechnology, specialty pharmaceuticals, drug discovery, medical technology, medical diagnostics and devices, and health care services sectors will give presentations...

SEATTLE, Nov. 7, 2018 /PRNewswire/ -- Impel NeuroPharma, a Seattle-based, privately-held biotechnology company focused on developing therapies for the treatment of central nervous system (CNS) disorders with unmet medical needs, today announced the appointment of Ellen A. Lubman as Chief Business Officer. In her role, Ellen's primary responsibilities are to...